Close Menu

NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market on Tuesday that its fiscal fourth quarter revenues rose 8 percent year over year.

For the three months ended June 30, total revenues were $200.5 million, compared to $186.5 million in the year-ago period, and missing the average expectation of Wall Street analysts for revenues of $193.7 million.

Revenues from molecular diagnostic testing were $187.9 million in fiscal Q4, up 8 percent from $173.7 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Apr
30
Sponsored by
Lexogen

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May
08
Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.

May
15
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how Radboud University Medical Center’s Department of Human Genetics is using exon-level copy number variant (CNV) detection by microarray to assist its efforts in constitutional genome testing. 

May
16
Sponsored by
PerkinElmer

This webinar will discuss a comprehensive end-to-end workflow for soil metagenomic shotgun sequencing that offers an unbiased alternative to amplicon-based approaches to assess the composition of culture-free microbial communities and predict functional profiles.